A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development
Dickinson, Michael (University of Melbourne)
Barba, Pere (Hospital Universitari Vall d'Hebron)
Jäger, Ulrich (Universitätskliniken der MedUni Wien)
Shah, Nirav N. (Medical College of Wisconsin)
Blaise, Didier (Aix-Marseille University)
Briones Meijide, Javier (Institut d'Investigació Biomèdica Sant Pau)
Shune, Leyla (University of Kansas Medical Center)
Boissel, Nicolas (Saint-Louis Hospital)
Bondanza, Attilio (Novartis Institutes for BioMedical Research)
Mariconti, Luisa (Novartis Institutes for BioMedical Research)
Marchal, Anne-Laure (Novartis Institutes for BioMedical Research)
Quinn, David S. (Novartis Institutes for BioMedical Research)
Yang, Jennifer (Novartis Institutes for BioMedical Research)
Price, Andrew (Novartis Institutes for BioMedical Research)
Sohoni, Akash (Novartis Institutes for BioMedical Research)
Treanor, Louise M. (Novartis Institutes for BioMedical Research)
Orlando, Elena J. (Novartis Institutes for BioMedical Research)
Mataraza, Jennifer (Novartis Institutes for BioMedical Research)
Davis, Jaclyn (Novartis Pharmaceuticals Corporation)
Lu, Darlene (Novartis Institutes for BioMedical Research)
Zhu, Xu (Novartis Institutes for BioMedical Research)
Engels, Boris (Novartis Institutes for BioMedical Research)
Moutouh-de Parseval, Laure (Novartis Institutes for BioMedical Research)
Brogdon, Jennifer L. (Novartis Institutes for BioMedical Research)
Moschetta, Michele (Novartis Institutes for BioMedical Research)
Flinn, Ian W. (Sarah Cannon Research Institute and Tennessee Oncology Center for Blood Cancers)
Universitat Autònoma de Barcelona

Data:	2023
Resum:	YTB323, a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, retains T-cell stemness after a manufacturing process time of less than 2 days and demonstrates clinical antitumor activity at significantly lower doses than traditionally manufactured CAR T cells. Traditional CAR T-cell manufacturing requires extended ex vivo cell culture, reducing naive and stem cell memory T-cell populations and diminishing antitumor activity. YTB323, which expresses the same validated CAR as tisagenlecleucel, can be manufactured in <2 days while retaining T-cell stemness and enhancing clinical activity at a 25-fold lower dose.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Publicat a:	Cancer Discovery, Vol. 13 (may 2023) , p. 1982-1997, ISSN 2159-8290

DOI: 10.1158/2159-8290.CD-22-1276
PMID: 37249512

16 p, 10.1 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats